A member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS) served as co-author of a study presented at San Antonio Breast Cancer Symposium.
Fort Myers, Florida — Medical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), served as co-author of a study shared in a poster presentation at the San Antonio Breast Cancer Symposium, which was held December 7-12, 2021.
Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study's analysis indicates a correlation between the TP53 gene and tumor volume following treatment with niraparib over time.
“Mutations in TP53 occur in 30% to 35% of invasive primary breast cancer cases and may be an effective biomarker. Nuraparib, a poly(ADP-ribose) polymerase (PARP)-1/2 inhibitor, provides a new, effective treatment option for BRCA 1/2-mutated early-stage breast cancer after chemotherapy,” said Dr Reeves and fellow researchers.